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Poster Session I S205. 39kg/M2. A more objective secondary analysis divided our pa-
tients’ BMI into quartiles was also used to explore risk threshold.
Results:The median BMI for our entire population was 33.9 (15.6-
57.6). The 100 daymortality in themyeloma andNHLpatients were
4/153 (2.6%) and 2/72 (2.7%), respectively. Using the above litera-
ture driven definitions, the data showed a significantly higher mor-
tality with increasing obesity (p\ 0.0001, see Table).
Table 1. Risk of Mortality by Degree of Obesity
BMI Group Alive Dead TotalTable 1. Characterstic
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25 (52.1%) <<35kg/m2 114 13 127
35-39 kg/m2 88 0 88
>39 kg/m2 12 5 17
Total 214 18 232p<.0001 (Chi-Square).
In the quartile analysis, there was one death in the lowest quartile, no
deaths in the second quartile, three deaths in the third quartile and
two deaths in the fourth quartile.
Conclusion:Our results mirror what other studies have found; that
increasing obesity is especially significant in a range above 30-35 kg/
M2 based solely on BMI classification. Our quartile analysis appears
to demonstrate a steep slope over our median (33.9kg/M2).
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RETROSPECTIVE COMPARISON OF DAY15 VERSUS DAY13 INITIATION
OF G-CSF IN MULTIPLE MYELOMA PATIENTS RECEIVING AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Koralkar, R., Hundley, B., Donna, S.E., Vaughan, W.P. University of
Alabama at BIrmingham, Birmingham, AL
Background: Filgrastim (G-CSF) administration after autologous
hematopoietic stem cell transplant (aHSCT) is routinely used to
shorten duration of neutropenia and risk of infection. The optimum
post transplant Day for startingG-CSF is not standardized.We have
historically used aHSCTDay13, but others have reported good re-
sults using Day 15.
Methods: Beginning 15 May 2009, patients with multiple myeloma
(MM) transplanted with myeloblative doses of melphalan and an
aHSCT24hours later receivedGCSF(250mg/m2) subcutaneouslydaily
fromDay15 until absolute granulocyte count (AGC) of 2000/mL.We
performed a validation after 49 patients comparing time to engraftment
of platelets and neutrophils compared to the immediately preceding 98
control patients given daily gCSF from Day 13 to the same AGC
endpoint.Additional endpoints includedstomatitis, transfusion support,
incidence of neutropenic fever, length of day, and 30 day mortality.
Results: There was no significant difference in number of CD341
cells infused among the two groups and there was no 30 day mortality
in either group.TheDay13 patients achievedneutrophil engraftment
a median of one day shorter than the Day15 patients (p\0.001, log-
rank). Median time to platelet recovery of more than 50  109/L was
two days earlier in Day 13 Group than Day 15 Group (p 5 0.02 in
log rank test). However, the rate of neutropenic fever rate was signifi-
cantly higher inDay13Group compared toDay15Group (62% vs.
42%, p 5 0.019). The rate of stomatitis was also higher in Day 13
Group compared to Day15 Group (82.7% vs. 52.1%, p5\0.001).Value
0.29†
0.79†
0.001*
0.023*
0.019†
0.001†Conclusion: Day 13 Administration of G-CSF provides early en-
graftment but there is increased rates for fever, stomatitis. The ap-
parent illogic of more neutropenic fever with faster white blood
cell (WBC) engraftment may be explained by better infectious dis-
ease prophylaxis in the more recent group.140
IMPACT OF CD34 CELL DOSE ON PLATELET ENGRAFTMENT AND
PLATELET TRANSFUSIONS FOLLOWING AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Shariatmadar, S.1, Pereira, D.2, Smith, R.2, Goodman, M.2 1University
of Miami Miller School of Medicine/Jackson Memorial Medical Center,
Miami, FL; 2University of Miami Miller School of Medicine/Jackson
Memorial Medical Center, Miami, FL
Introduction: Maximizing the CD34 cell content of the graft has
been reported to lead to faster platelet engraftment and lower
requirement for platelet transfusions in patients undergoing autolo-
gous stem cell transplantation (A-HSCT). We evaluated the impact
of CD34 cell dose on platelet recovery and transfusion requirements
in 114 consecutive adults undergoing A-HSCT with a CD34 cell
dose of . 2  106/kg recipient body weight (BW) infused.
Methods: From January 2007 to March 2010, 114 adults with NHL
(n: 45), multiple myeloma (n: 44), Hodgkin’s disease (n: 23) and AML
(n: 2) underwent apheresis (range: 1-7) and A-HSCT. Patients were
categorized in to 3 groups based on the CD341 cell dose transplanted
[group 1: 2.0-2.99  106 (n: 55), group 2: 3.0-5.0  106 (n: 38) and
group 3: . 5  106 CD34/kg recipient BW (n: 21)]. Neutrophil
and Platelet engraftment (platelet count. 20,000/ul for 2 consecutive
days without platelet support) and transfusion requirements post-
transplant were evaluated and correlated with patient’s age, diagnosis
and number of apheresis.
Results: Median neutrophil engraftment following transplantation
was 11 days in all groups, while median platelet engraftment was 14
days in group 1 and 13 days in groups 2 and 3. Platelet recovery by
days 30 and 60 was 90.7%/96.3% in group 1, 94.7%/100% in group
2, 90.5%/95.2% in group 3. Two patients with NHL in group 1
(3.6%) and one with AML in group 3 (4.8%) were platelet-dependent
. 60 days post-transplantation. One patient withNHL in group 1 ex-
pired on day 6 from transplant-related complications.Median platelet
transfusions were 3 doses of platelets in group 1 and 2 doses in other
groups. Patient’s age, diagnosis and number of apheresis did not affect
30 and 60 day platelet recovery/transfusions post-transplant. Nine pa-
tients (7.9%) received plerixafor-mobilized transplants with median
platelet engraftment 14 days post-transplant.
Conclusion: CD34 cell dose did not significantly impact platelet re-
covery and transfusion requirements post-transplantation with rapid
platelet recovery achievable with CD34 cell dose . 2  106/kg rec
BW. Other factors including the number of platelet precursors in
the transplanted product rather than CD34 cell dose may be a more
important indicator of platelet recovery post-transplantation.141
EFFICACY AND SAFETY OF HEMATOPOIETIC STEM CELL REMOBILIZA-
TION WITH PLERIXAFOR (MOZOBIL) 1 G-CSF IN PATIENTS WITH
GERM CELL TUMOR
Schriber, J.1, Horwitz, M.2, Libby, E.3, Huebner, D.4, Mody, P.D.4,
Holman, P. 1Banner Blood and Marrow Transplant Program, Phoe-
nix, AZ; 2Duke University Medical Center, Durham, NC; 3UNM
Cancer Center, Albuquerque, NM; 4Genzyme Corporation, Cam-
bridge, MA
Autologous hematopoietic stem cell transplantation can be cura-
tive for patients (pts) with germ cell tumors (GCT). Many such pts
are heavily pretreated. Moreover, most protocols call for tandem
transplant requiring higher cell yields. This creates a situation
where many pts are unable to successfully mobilize adequate cells.
Mobilization with plerixafor (P)1 G-CSF (G) is safe and effective
for pts with myeloma and lymphoma. Herein we describe the safety
